Cytek Biosciences (CTKB) Gains from Investment Securities (2020 - 2026)

Cytek Biosciences has reported Gains from Investment Securities for 7 years, with the latest figure at -$236000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to -$236000.0; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 4.53% YoY), and the FY2025 full-year result was $5.0 million, up 31.61% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$236000.0, down from $5.4 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $7.9 million in Q2 2023, with the low at -$10.0 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged $591866.4 across 5 years, with a median of $777375.5 in 2022.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities sank 1701.12% — and 2024, when it surged 27128.57%.
• Cytek Biosciences' Gains from Investment Securities stood at -$10.0 million in 2022, then jumped by 100.07% to $7000.0 in 2023, then surged by 27128.57% to $1.9 million in 2024, then surged by 182.95% to $5.4 million in 2025, then sank by 104.38% to -$236000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$236000.0 (Q1 2026), $5.4 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.